Explore 3 Stock Ideas & Industry Insights Download Free Report

18889881171
Shopping Cart 0
countryflagUS
Login

Journey Medical Corp

Healthcare US DERM

6.43USD
0.21(3.38%)

Last update at 2026-06-22T20:01:00Z

Day Range

6.256.72
LowHigh

52 Week Range

4.319.55
LowHigh

Fundamentals

  • Previous Close 6.22
  • Market Cap172.60M
  • Volume334251
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-3.91400M
  • Revenue TTM61.86M
  • Revenue Per Share TTM2.52
  • Gross Profit TTM 40.93M
  • Diluted EPS TTM-0.47

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -11.37100M -14.61100M -3.63200M -29.56500M -42.36000M
Minority interest - - - - -
Net income -11.43100M -14.67200M -3.85300M -29.62800M -43.99400M
Selling general administrative 44.37M 40.20M 48.06M 59.47M 39.83M
Selling and marketing expenses - - - - -
Gross profit 36.68M 35.26M 52.52M 42.89M 31.05M
Reconciled depreciation 4.35M 3.52M 4.26M 4.37M 2.56M
Ebit -8.17200M -11.91100M -1.93400M -27.51700M -25.34100M
Ebitda -3.82600M -8.39600M 1.92M -27.45700M -25.33900M
Depreciation and amortization 4.35M 3.52M 3.85M 0.06M 0.00200M
Non operating income net other - - - - -
Operating income -8.17200M -13.67700M -2.07300M -27.51700M -25.34100M
Other operating expenses 70.03M 69.81M 81.25M 101.19M 88.47M
Interest expense 3.70M 2.70M 1.70M 2.02M 7.03M
Tax provision 0.06M 0.06M 0.11M 0.06M 1.63M
Interest income 0.59M 0.76M 0.26M 0.06M 0.00200M
Net interest income -3.10900M -1.94300M -2.03200M -1.95900M -7.03200M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 0.06M 0.06M 0.22M 0.06M 1.63M
Total revenue 61.86M 56.13M 79.18M 73.67M 63.13M
Total operating expenses 44.85M 48.93M 54.59M 70.41M 56.39M
Cost of revenue 25.18M 20.88M 26.66M 30.77M 32.08M
Total other income expense net -3.19900M -0.93400M -1.55900M -2.04800M -17.01900M
Discontinued operations - - - - -
Net income from continuing ops -11.43100M -14.67200M -12.35200M -29.62800M -43.99400M
Net income applicable to common shares - - - -29.62800M -43.99400M
Preferred stock and other adjustments - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 94.59M 80.24M 76.85M 105.16M 97.28M
Intangible assets 27.61M 31.86M 20.29M 27.20M 12.55M
Earning assets - - - - -
Other current assets 3.38M 3.21M 3.59M 3.31M 2.44M
Total liab 62.74M 60.17M 56.50M 88.18M 55.24M
Total stockholder equity 31.85M 20.07M 20.35M 16.98M 42.04M
Deferred long term liab - - - - -
Other current liab 27.96M 18.36M 20.37M 27.23M 4.51M
Common stock 0.00200M 0.00200M 0.00200M 0.00200M 0.00200M
Capital stock 0.00300M 0.00200M 0.00200M 0.00200M 0.00200M
Retained earnings -98.45800M -87.02700M -72.35500M -68.50200M -38.87400M
Other liab - - - - 0.00800M
Good will - - - - -
Other assets - - - 0.10M 0.15M
Cash 24.09M 20.30M 27.44M 32.00M 49.08M
Cash and equivalents - - - - -
Total current liabilities 37.44M 35.17M 41.87M 66.83M 51.61M
Current deferred revenue - -0.58800M 0.05M - 23.37M
Net debt -23.97100M 5.40M -9.70900M -9.03800M -48.17100M
Short term debt 0.10M 0.71M 3.10M 3.03M 0.91M
Short long term debt - - - 2.95M 0.81M
Short long term debt total 0.12M 25.70M 17.73M 22.96M 0.91M
Other stockholder equity 130.31M 107.09M 92.70M 85.48M 80.92M
Property plant equipment - - - 0.19M 0.09M
Total current assets 66.87M 48.18M 56.45M 77.68M 84.49M
Long term investments - - - - -
Net tangible assets - - - -10.21500M 29.49M
Short term investments - - - - -
Net receivables 29.78M 10.23M 15.22M 28.21M 23.11M
Long term debt 25.28M 24.88M 14.62M 19.83M -
Inventory 9.62M 14.43M 10.21M 14.16M 9.86M
Accounts payable 9.31M 16.05M 18.34M 36.57M 22.81M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - - - - -
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other - - 0.00600M 0.10M 0.15M
Deferred long term asset charges - - - - -
Non current assets total 27.72M 32.06M 20.39M 27.48M 12.79M
Capital lease obligations 0.12M 0.20M 0.11M 0.19M 0.10M
Long term debt total - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - -15.00000M -5.00000M -20.00000M -10.00000M
Change to liabilities - - - 0.00000M 21.71M
Total cashflows from investing activities - -15.00000M -5.00000M - -10.00000M
Net borrowings 15.73M 16.63M -4.45400M - 5.05M
Total cash from financing activities 16.23M 16.99M -4.80400M 16.46M 53.02M
Change to operating activities - - - - 0.78M
Net income -11.43100M -14.67200M -3.85300M -29.62800M -43.99400M
Change in cash 3.79M -7.13400M -4.56400M -17.07800M 40.84M
Begin period cash flow 20.30M 27.44M 32.00M 49.08M 8.25M
End period cash flow 24.09M 20.30M 27.44M 32.00M 49.08M
Total cash from operating activities -12.44100M -9.12700M 5.24M -13.53400M -2.18100M
Issuance of capital stock - - 4.49M 0.00000M 51.50M
Depreciation 4.72M 3.42M 3.85M 4.37M 2.56M
Other cashflows from investing activities - -15.00000M -5.00000M - -
Dividends paid - - - - -
Change to inventory 4.81M -4.22500M 3.95M 1.74M -8.45800M
Change to account receivables -19.34100M 4.47M 12.55M -5.38000M 0.77M
Sale purchase of stock - - - - -
Other cashflows from financing activities -0.07500M 0.37M -0.35000M 24.69M 31.97M
Change to netincome - - - - 21.97M
Capital expenditures 0.00000M 15.00M 5.00M 0.00000M 10.00M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -11.89900M -3.76600M -1.65500M 6.19M 14.71M
Stock based compensation 6.29M 6.10M 2.61M 4.42M 2.47M
Other non cash items -0.12300M -0.21100M 4.29M 1.12M 20.51M
Free cash flow -12.44100M -9.12700M 0.24M -13.53400M -12.18100M

Peer Comparison

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
DERM
Journey Medical Corp		 0.21 3.38% 6.43 - 172.41 2.79 4.47 2.32 17.72
ZTS
Zoetis Inc		 -2.82 3.58% 75.89 40.18 30.96 10.67 17.60 11.27 26.18
MKKGY
Merck KGaA ADR		 -0.19 0.62% 30.56 21.25 14.93 3.10 2.14 3.60 12.98
MKGAF
MERCK Kommanditgesellschaft auf Aktien		 - -% 157.12 21.73 14.95 3.16 2.15 3.56 12.82
GALDY
GALDERMA GROUP AG		 - -% 42.94 74.21 41.67 8.64 5.55 9.15 42.22

Reports Covered

Stock Research & News

View All

Profile

Journey Medical Corporation, a commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris. It also provides Zilxi, a topical minocycline treatment for inflammatory lesions of rosacea; Emrosi for the treatment of inflammatory lesions of rosacea; Exelderm cream and solution for the treatment of fungal skin infections; and Targadox, an oral doxycycline drug for adjunctive therapy for severe acne, as well as Luxamend, a water-based emulsion formulated to provide a moist healing environment for superficial wounds; minor cuts or scrapes; dermal ulcers; donor sites; first- and second-degree burns, including sunburns; and radiation dermatitis. The company was formerly known as Coronado Dermatology, Inc. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona.

Journey Medical Corp

9237 East Via de Ventura Blvd., Scottsdale, AZ, United States, 85258

Key Executives

Name Title Year Born
Dr. Lindsay Allan Rosenwald Exec. Chairman 1955
Mr. Claude Maraoui Founder, Pres, CEO & Director 1967
Mr. Ernest Robert De Paolantonio CPA, CPA, M.B.A., MBA Chief Financial Officer 1953
Mr. Andrew J. Zwible VP of Operations NA
Mr. Ramsey Alloush Gen. Counsel & Company Sec. 1986
Mr. Ernest Galvan VP of Marketing & Strategy 1962
Mr. Robert Nevin Chief Commercial Officer 1968
Robyn Hunter Treasurer & Sec. NA
Dr. Lindsay Allan Rosenwald Executive Chairman 1955
Mr. Claude Maraoui Founder, President, CEO & Director 1967

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.